FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021668065> ?p ?o ?g. }

• W2021668065 endingPage "323" @default.
• W2021668065 startingPage "315" @default.
• W2021668065 abstract "Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events. Although bile acid sequestrants were the first class of drugs to show a mortality benefit related to LDL-C lowering, statins are now considered first-line pharmacological therapy for reducing LDL-C levels because of their potency and their remarkable record of successful outcomes studies. Nevertheless, a substantial proportion of patients do not achieve LDL-C goals with statin monotherapy. In addition, because of adverse effects (primarily myopathy), some patients may be unwilling to use or unable to tolerate statin therapy at all or may not tolerate a full therapeutic statin dose. Also, statins may increase risk of new-onset diabetes in patients at high risk for diabetes. Thus, there remains a need for other lipid-lowering drugs to be used in combination with or in place of statins. The purpose of this article is to review available data from the literature on the use of colesevelam, a second-generation bile acid sequestrant, in combination with other lipid-lowering agents. Colesevelam has been studied in combination with statins, niacin, fibrates, and ezetimibe (including some three-drug combinations). An additive reduction in LDL-C was seen with all combinations. Other observed effects of colesevelam in combination with other lipid-lowering drugs include reductions in apolipoprotein (apo) B (with statins, fibrates, ezetimibe, statin plus niacin, or statin plus ezetimibe) and high-sensitivity C-reactive protein (with statins), and increases in apo A-I (with statins, ezetimibe, or statins plus niacin). Triglyceride levels remained relatively unchanged when colesevelam was combined with statins, fibrates, ezetimibe, or statin plus ezetimibe, and decreased with the triple combination of colesevelam, statin, and niacin. Colesevelam offset the negative glycemic effects of statins and niacin in subjects with insulin resistance or impaired glucose tolerance. Colesevelam was generally well tolerated when added to other lipid-lowering therapies in clinical trials, with gastrointestinal effects such as constipation being the predominant adverse events. Since colesevelam is not absorbed and works primarily in the intestine, it has a low potential for systemic metabolic drug–drug interactions with other drugs. Colesevelam has been shown to not interact with the lipid-lowering drugs lovastatin and fenofibrate; where interaction may be anticipated, separating dosing times by 4 h reduces the impact of any interaction. Available data confirms that colesevelam has additive cholesterol-lowering effects when used in combination with other lipid-lowering therapies. Furthermore, in some patient populations, the additional glucose-lowering effect of colesevelam may be beneficial in offsetting hyperglycemic effects of other lipid-lowering drugs." @default.
• W2021668065 created "2016-06-24" @default.
• W2021668065 creator A5009294113 @default.
• W2021668065 creator A5017679504 @default.
• W2021668065 date "2013-08-03" @default.
• W2021668065 modified "2023-10-14" @default.
• W2021668065 title "Role of Colesevelam in Combination Lipid-Lowering Therapy" @default.
• W2021668065 cites W1523152575 @default.
• W2021668065 cites W1587435290 @default.
• W2021668065 cites W1587888282 @default.
• W2021668065 cites W1591834330 @default.
• W2021668065 cites W1963958736 @default.
• W2021668065 cites W1965975466 @default.
• W2021668065 cites W1970771772 @default.
• W2021668065 cites W1971627211 @default.
• W2021668065 cites W1972661406 @default.
• W2021668065 cites W1974882957 @default.
• W2021668065 cites W1977208802 @default.
• W2021668065 cites W1993796214 @default.
• W2021668065 cites W1994316655 @default.
• W2021668065 cites W1998939122 @default.
• W2021668065 cites W2001774934 @default.
• W2021668065 cites W2004549247 @default.
• W2021668065 cites W2007861083 @default.
• W2021668065 cites W2009674945 @default.
• W2021668065 cites W2012345406 @default.
• W2021668065 cites W2016598185 @default.
• W2021668065 cites W2025422355 @default.
• W2021668065 cites W2036303969 @default.
• W2021668065 cites W2046189497 @default.
• W2021668065 cites W2055835176 @default.
• W2021668065 cites W2061611908 @default.
• W2021668065 cites W2067046315 @default.
• W2021668065 cites W2071802081 @default.
• W2021668065 cites W2072946847 @default.
• W2021668065 cites W2076565086 @default.
• W2021668065 cites W2083270733 @default.
• W2021668065 cites W2085737093 @default.
• W2021668065 cites W2085942677 @default.
• W2021668065 cites W2093260782 @default.
• W2021668065 cites W2093866061 @default.
• W2021668065 cites W2103108681 @default.
• W2021668065 cites W2106343349 @default.
• W2021668065 cites W2115169717 @default.
• W2021668065 cites W2118184073 @default.
• W2021668065 cites W2129875389 @default.
• W2021668065 cites W2130771193 @default.
• W2021668065 cites W2138109132 @default.
• W2021668065 cites W2139353545 @default.
• W2021668065 cites W2140072878 @default.
• W2021668065 cites W2142264046 @default.
• W2021668065 cites W2143465004 @default.
• W2021668065 cites W2144577176 @default.
• W2021668065 cites W2145146113 @default.
• W2021668065 cites W2147133240 @default.
• W2021668065 cites W2151349993 @default.
• W2021668065 cites W2153303712 @default.
• W2021668065 cites W2153535950 @default.
• W2021668065 cites W2155243965 @default.
• W2021668065 cites W2155598961 @default.
• W2021668065 cites W2158474131 @default.
• W2021668065 cites W2163547584 @default.
• W2021668065 cites W2165605025 @default.
• W2021668065 cites W2321230622 @default.
• W2021668065 cites W2510708214 @default.
• W2021668065 cites W34443605 @default.
• W2021668065 cites W4230870013 @default.
• W2021668065 cites W4232177732 @default.
• W2021668065 cites W4248021162 @default.
• W2021668065 cites W4254363271 @default.
• W2021668065 doi "https://doi.org/10.1007/s40256-013-0037-0" @default.
• W2021668065 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3781306" @default.
• W2021668065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23913404" @default.
• W2021668065 hasPublicationYear "2013" @default.
• W2021668065 type Work @default.
• W2021668065 sameAs 2021668065 @default.
• W2021668065 citedByCount "28" @default.
• W2021668065 countsByYear W20216680652014 @default.
• W2021668065 countsByYear W20216680652016 @default.
• W2021668065 countsByYear W20216680652017 @default.
• W2021668065 countsByYear W20216680652018 @default.
• W2021668065 countsByYear W20216680652019 @default.
• W2021668065 countsByYear W20216680652021 @default.
• W2021668065 countsByYear W20216680652022 @default.
• W2021668065 countsByYear W20216680652023 @default.
• W2021668065 crossrefType "journal-article" @default.
• W2021668065 hasAuthorship W2021668065A5009294113 @default.
• W2021668065 hasAuthorship W2021668065A5017679504 @default.
• W2021668065 hasBestOaLocation W20216680651 @default.
• W2021668065 hasConcept C126322002 @default.
• W2021668065 hasConcept C134018914 @default.
• W2021668065 hasConcept C197934379 @default.
• W2021668065 hasConcept C2776839432 @default.
• W2021668065 hasConcept C2776999253 @default.
• W2021668065 hasConcept C2778163477 @default.
• W2021668065 hasConcept C2778657065 @default.
• W2021668065 hasConcept C2779091943 @default.
• W2021668065 hasConcept C2780092750 @default.

• next